Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

Chief Executive Officer and Co-Founder of Raptor, commented, "As a clinical-stage company with multiple active programs, we are pleased to welcome Dr. Rioux. This is an ideal time for Patrice to join Raptor. We believe his successful clinical and regulatory track record will serve us well as we prepare for a pivotal clinical trial in our lead clinical program, DR Cysteamine in cystinosis, and position us to advance our other clinical-stage programs through the clinic and into the market."

Dr. Rioux said, "I am excited to join the team at Raptor, as I believe in the potential of the Company's pipeline of clinical-stage drug candidates that address some serious unmet medical needs."

Status of Raptor's Clinical-Stage Development Programs

Under Dr. Rioux' guidance, the Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010.

In February, 2009, Raptor announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate a prototype formulation of DR Cysteamine in juvenile patients diagnosed with NASH. Results from that study are expected later this year.

In November, 2008, Raptor entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate DR Cysteamine in a two-year, multi-center Phase II clinical trial in Huntington's, sponsored by CHU d'Angers and supported by a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health. Initiation of the Phase II Huntington's study, in which Raptor will supply the study drug, is planned for late 2009.

Also in November 2008, Raptor announced results of its Phase 2a study of Convivia in 32 ALDH2-deficient subjects of Japanese descent. The Company is actively exploring partnering opportunities for Convi
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cardium Therapeutics,(Amex: CXM ) and its ... findings from a preclinical study, demonstrating a ... (cooling) for the potential,treatment of acute myocardial ... BioMed Central (BMC) Cardiovascular Disorders (2008, 8:7, ...
... - New Approach to Targeting the Tumor ... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... the extracellular matrix, today,announced new pre-clinical findings ... the American Association for Cancer Research (AACR) ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 4
(Date:7/10/2014)... According to a new market research ... Airborne, Naval), Application (Software Defined Radios, SATCOM, Encryption, ... America, Asia-Pacific, Europe, the Middle East & ROW) ... the market is estimated to be $30.15 billion ... CAGR of 5.56% to reach $39.52 billion by ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
(Date:7/10/2014)... not nurture, may play the bigger role in the ... "As is the case in humans, genes matter ... William Hopkins of the Yerkes National Primate Research Center ... journal Current Biology . The findings might ... humans, Hopkins, team said. According to the researchers, ...
(Date:7/10/2014)... who are sensitive to light or noise after a ... as anxiety and depression, a new study says. ... teens experience after concussion may help in planning for ... to return to play and what accommodations are needed ... and Dong Han, of the University of Kentucky in ...
Breaking Medicine News(10 mins):Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... , , IRVING, Texas, ... (OTC Bulletin Board: RBCL), a provider of proprietary nutritional supplements and ... the ClearPay System, a compensation plan that rewards the company,s independent ... The ClearPay System is the ...
... , , , ... with painful conditions, September is a time for their true ... communication, National Pain Awareness Month allows people with painful conditions ... fight their pain. , , Fibromyalgia has ...
... of infections on campus already increasing rapidly; could ... , TUESDAY, Sept. 8 (HealthDay News) -- Erica Goldfine, ... to school this semester to find a new item ... cheating: emergency preparedness procedures for the H1N1 swine flu. ...
... , CLAREMONT, Calif., Sept. 8 ... that personalized medicine will have on life science companies, physicians, patients, ... "Personalized medicine will change how medicine is delivered," said Diana Bartlett, ... longer one size fits all. Your therapy may be different from ...
... Ala., Sept. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ... two upcoming investor conferences. , , ... to present a corporate summary at the Rodman & Renshaw Annual ... Eastern Time. The conference will be held September 9-11, 2009 in ...
... , , JACKSONVILLE, Fla., Sept. 8 ... to getting the job done. Yet, new research reveals that as they ... to perform everyday activities at home and on the job. , ... are concerned that their vision is getting worse as they age, and ...
Cached Medicine News:Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 2Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 3Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 2Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 3Health News:Colleges Move to Limit Swine Flu's Spread 2Health News:Colleges Move to Limit Swine Flu's Spread 3Health News:Colleges Move to Limit Swine Flu's Spread 4Health News:KGI to Host Public Discussion on Personalized Medicine 2Health News:BioCryst Executives to Present at Two Investor Conferences 2Health News:Working Moms' Vision Not 'Near' Perfect 2Health News:Working Moms' Vision Not 'Near' Perfect 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: